Coloplast A/S (Coloplast A/S) Cash And Cash Equivalents : $134 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Coloplast A/S Cash And Cash Equivalents?

Coloplast A/S's quarterly cash and cash equivalents increased from Jun. 2023 ($124.42 Mil) to Sep. 2023 ($130.37 Mil) and increased from Sep. 2023 ($130.37 Mil) to Dec. 2023 ($134.02 Mil).

Coloplast A/S's annual cash and cash equivalents declined from Sep. 2021 ($70.88 Mil) to Sep. 2022 ($55.08 Mil) but then increased from Sep. 2022 ($55.08 Mil) to Sep. 2023 ($130.37 Mil).

Coloplast A/S Cash And Cash Equivalents Historical Data

The historical data trend for Coloplast A/S's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast A/S Cash And Cash Equivalents Chart

Coloplast A/S Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash And Cash Equivalents

Get a 7-Day Free Trial

52.52

51.15

70.88

55.08

130.37

Coloplast A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															95.55	90.33	124.42	130.37	134.02

Coloplast A/S Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Coloplast A/S (OTCPK:CLPBF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Coloplast A/S Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Coloplast A/S's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Coloplast A/S (Coloplast A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast A/S (OTCPK:CLPBF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

CLPBY:USA COLOBc:UK 0QBO:UK COLO B:Denmark CBHD:Germany

Address

Holtedam 1-3, Humlebaek, DNK, DK-3050

Website

https://www.coloplast.com

Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Coloplast A/S (Coloplast A/S) Headlines

From GuruFocus

Coloplast A/S's Dividend Analysis

By GuruFocus Research • 12-07-2023